{
    "code": "56034187",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=56034187",
    "time": "2022-12-23 05:01:27",
    "許可證字號": "衛部醫器輸字第034187號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "QSD7002",
    "有效日期": "115\/01\/07",
    "發證日期": "110\/01\/07",
    "許可證種類": "醫　器",
    "舊證字號": "",
    "醫療器材級數": "第三等級",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05603418707",
    "中文品名": "“凱杰” 纖維母細胞生長因子受體擴增反應突變檢驗試劑組",
    "英文品名": "“QIAGEN” therascreen FGFR RGQ RT-PCR Kit",
    "效能": "本產品是一種即時定量反轉錄PCR檢測，用於對從福馬林固定石蠟包埋(formalin-fixed paraffin-embedded，FFPE)泌尿道上皮腫瘤組織獲取的RNA樣本內的纖維母細胞生長因子受體3(FGFR3)基因中外顯子7的兩個點突變(p.R248C[c.742C>T]和p.S249C[c.746C>G])、外顯子10的兩個點突變(p.G370C[c.1108G>T]和p.Y373C[c.1118A>G])和兩個融合基因(FGFR3-TACC3v1和FGFR3-TACC3v3)進行定性檢測。此檢測適用於輔助識別因存在這些改變而符合使用BALVERSA(erdafitinib)治療條件的泌尿道上皮癌(urothelial cancer，UC)患者。",
    "醫器規格": "874711，以下空白。",
    "劑型": "",
    "包裝": "",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "醫器主類別一": "B血液學及病理學裝置",
    "醫器次類別一": "B4020分析特定試劑",
    "醫器主類別二": "",
    "醫器次類別二": "",
    "醫器主類別三": "",
    "醫器次類別三": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "",
    "限制項目": "02輸　入 36GMP",
    "申請商名稱": "620118K794  凱杰生物科技有限公司",
    "申請商地址": "臺北市中正區羅斯福路2段100號5樓",
    "主製造廠": [
        {
            "製造廠名稱": "MDE0446100  QIAGEN GMBH",
            "製造廠廠址": "QIAGEN STRASSE 1, 40724 HILDEN, GERMANY",
            "製造廠公司地址": "",
            "製造廠國別": "GERMANY",
            "製程": ""
        }
    ],
    "藥理治療分類": "",
    "ingredients": [],
    "仿單外盒": [
        {
            "title": "560341870001-110-05-01.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=56034187&Seq=001&Type=9"
        },
        {
            "title": "560341870002-110-05-01.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=56034187&Seq=001&Type=8"
        }
    ]
}